Overview

• SBI-810, developed at Duke University, uses biased agonism at neurotensin receptor 1 to provide pain relief without causing euphoria or dependence.
• In preclinical mouse studies, the compound effectively alleviated acute and chronic pain from surgical incisions, fractures, and nerve injuries.
• The drug outperformed opioids like oliceridine and nerve-pain treatments such as gabapentin, showing fewer side effects and no sedation or memory issues.
• SBI-810 prevented opioid-related side effects like constipation and tolerance buildup, and enhanced the effectiveness of opioids at lower doses when used together.
• Researchers have secured multiple patents for SBI-810 and are preparing for the first human clinical trials to further evaluate its safety and efficacy.